Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-09-26
2006-09-26
Graser, Jennifer E. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S249100, C424S250100, C424S203100, C424S197110, C424S193100, C536S123100
Reexamination Certificate
active
07112332
ABSTRACT:
An immunogenic complex, essentially consisting of neisserial outer membrane protein proteosomes hydrophobically complexed to native purified bacterial lipopolysaccaride and formulated in accordance with the current invention for mucosal delivery such as via the oral or intranasal route is used as a vaccine. Specifically, a vaccine usingshigellalipopolysaccharides complexed to proteosomes for such mucosal administration induces IgG and IgA antibodies in sera and in respiratory and intestinal fluids. Furthermore, such antibodies are associated with protection against shigella infection and these vaccines are herein demonstrated to protect against mucosal infection with shigella.
REFERENCES:
patent: 4707543 (1987-11-01), Zollinger et al.
patent: 5985284 (1999-11-01), Lowell
Black et al. J.Infect.Dis. 1987, 155(6): 1260-1265.
Cohen et al. J. Infect.Dis. 1988. 157(5): 1068-1071.
Ruegg et al. J. Immunolog. Methods. 1990. 135: 101-109.
Formal and Levine, in Bacterial Vaccines (1994), pp. 167-186.
Formal et al., Proc. Soc. Exp. Biol. Med. (1967) 25:347-349.
Herrington et al., Vaccine (1990) 8:353-357.
Keusch and Bennish, in Bacterial Infection of Human (2nd ed.), Evans and Brachman (eds.), New York and London: Plenum Medical (1990), p. 593-620.
Livingston et al., Vaccine (1993) 11(12):1149-1203.
Lowell et al., J. Exp. Med. (1988) 167:658-663.
Lowell et al., Science (1988) 240:800-802.
Mallett et al., Infect. Immun. (1995) 63(6):2382-2386.
Orr et al., American Society for Microbiol. 93rd Gen. Meeting. May 16-20, 1993. Atlanta. E-58 & E59.
Orr et al., Infect. Immun. (1993) 61(6):2390-2395.
Orr et al., Infect. Immun. (1994) 62(11):5198-5200.
Ruegg et al., J. Immunol. Methods. (1990) 135:101-109.
Underdown and Schiff, Ann. Rev. Immunol. (1986) 4:389-417.
Graser Jennifer E.
The United States of America as represented by the Secretary of
LandOfFree
Oral or intranasal vaccines using hydrophobic complexes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral or intranasal vaccines using hydrophobic complexes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral or intranasal vaccines using hydrophobic complexes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3579254